Bitcoin ETF trade volumes retreat from record level — but stay high
BTC funds from BlackRock, Grayscale Investments and Fidelity each notched at least $1 billion in trade volumes Thursday as crypto rally continues
Bitcoin ETF trade volumes quieted down slightly Thursday following a record showing — but remained well above average amid the ongoing crypto rally.
The roughly $4.7 billion in trading volumes was the second-best total for the 10 US bitcoin funds since launching on Jan. 11.
The volumes indicate sustained investor appetite for the once-elusive products about two months away from a bitcoin halving event set to slow the creation of new bitcoin.
Read more: How the halving could impact bitcoin’s price
BlackRock ’s iShares Bitcoin Trust (IBIT) finished the day just shy of $1.9 billion in trading volumes, according to Yahoo Finance data — down from the high of roughly $3.3 billion it posted on Wednesday.
Matt Hougan, chief investment officer of Bitwise, said during a Thursday interview with CNBC that bitcoin’s supply-demand dynamic is “off the hook.”
Bitcoin’s price ( BTC ) was about $61,100 at 4:30 pm ET on Thursday — up nearly 18% from a week ago and about 1.3% in the last 24 hours.
IBIT’s volumes led all bitcoin ETFs Wednesday on a day where the segment notched record volumes amounting to $7.6 billion — a total that shattered the previous high of about $4.5 billion set on Jan. 11.
The BlackRock fund was the leader again Thursday, as it tallied more than $1 billion in trade volumes for a fourth straight day.
As part of Wednesday’s record bitcoin ETF volumes day, the Grayscale Bitcoin Trust ETF ( GBTC ) and the Fidelity Wise Origin Bitcoin Fund (FBTC) contributed $1.8 billion and $1.4 billion, respectively.
GBTC’s trade volumes dipped to nearly $1.4 billion on Thursday. FBTC’s volumes dropped too, but stayed slightly above $1 billion.
The elevated volume levels have translated to net inflows, with bitcoin ETFs seeing all-time high net inflows of $673 million on Wednesday, BitMEX Research data indicates. That record came despite $216 million exiting higher-priced GBTC.
Flow data for Thursday was not available at time of publication.
Don’t miss the next big story – join our free daily newsletter .
- bitcoin etf
- BlackRock
- ETFs
- GBTC
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint
As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.
"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight
KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.
AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week
Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs
Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.
Crypto prices
More
